Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001002875
Ethics application status
Approved
Date submitted
29/05/2021
Date registered
30/07/2021
Date last updated
12/07/2022
Date data sharing statement initially provided
30/07/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Investigating the safety and tolerability of ONC201 in healthy adults - Part A
Scientific title
A Phase 1, randomized study to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating single, oral doses of ONC201 and the effects of food on the bioavailability of ONC201 following oral administration in healthy adult subjects - Part A
Secondary ID [1] 304351 0
Protocol Number: ONC201-101 - Part A
Universal Trial Number (UTN)
Trial acronym
Linked study record
This record is one part out of three parts of the ONC201-101 study, part B1 is registered as ACTRN12621000975897 and part B2 is registered as ACTRN12621001003864

Health condition
Health condition(s) or problem(s) studied:
Cancer 322124 0
Condition category
Condition code
Cancer 319829 319829 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Part A (Treatment 1) - All treatment periods will be open label. All participants will receive ONC201 (one oral capsule at each dose) in sequential, non-randomised, escalating doses of 125 mg in Period 1, 375 mg in Period 2, and 625 mg in Period 3. Only 1 single dose will be given in each period. There will be a wash out period of 1 week between each dose. All doses will be administered in the clinic. and will be administered under a fasting condition (nothing but water for at least 10 hours prior to dosing and 1 hour post dosing).
Intervention code [1] 320707 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 327699 0
To characterize plasma ONC201 Cmax, Tmax, AUClast, AUCinf, %AUCextrap, t1/2, CL/F, Vz/F following single escalating doses of ONC201 administered orally in healthy adults
Timepoint [1] 327699 0
Blood samples will be taken predose (within 15 minutes prior to dosing) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 168 hours post dose.
Primary outcome [2] 328029 0
To characterize plasma metabolite (ONC207) Cmax, Tmax, AUClast, AUCinf, %AUCextrap, t1/2 following single escalating doses of ONC201 administered orally in healthy adults
Timepoint [2] 328029 0
Blood samples will be taken predose (within 15 minutes prior to dosing) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 168 hours post dose.
Primary outcome [3] 327700 0
To investigate the safety and tolerability ( by review of clinical and laboratory safety parameters including: AEs, absolute and changes over time of hematology, clinical chemistry, vital signs, and ECG intervals) following single escalating doses of ONC201 administered orally in healthy adults in all parts of the study
Timepoint [3] 327700 0
laboratory safety parameters taken on screening, on Days -1, 3, and 7 in each treatment period, and at the Follow Up (FU)/Withdrawal (WD) visit
Adverse events (AEs) reviewed continually throughout the trial,
Vital signs - (blood pressure, respiratory rate, pulse rate, and temperature) will be measured at screening, on Days -1, 1, and 3 in each treatment period, and at the FU/WD visit, On Day 1 in each treatment period, measurements will be taken predose (3 replicates at 1-minute intervals, performed 1 hour prior to dosing) and at approximately 3 hours post dose.
ECG- will be performed at screening, on Day 1 and 3 in each treatment period, and at the FU/WD visit. On Day 1, ECGs will be obtained predose and at approximately 2, 4, 8, and 24 hours post dose.
Secondary outcome [1] 396260 0
To characterize urine ONC201 Ae, Ae(%), CLr following single escalating doses of ONC201 administered orally in healthy adults
Timepoint [1] 396260 0
Urine Samples will be collected at Day 1: Predose (in the morning prior to dosing) and during the following intervals 0-4, 4-8, 8-12, and 12-24 hours post dose for each period.

Eligibility
Key inclusion criteria
1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions in this protocol.
2. Male or female between 18 to 55 years of age.
3. Female must be of non-childbearing potential i.e., postmenopausal woman or a premenopausal woman documented as surgically sterile following either a hysterectomy and/or bilateral oophorectomy, tubal ligation or placement of bilateral fallopian tube occlusion, or with medically documented ovarian failure.
4. Males must be surgically sterilized OR must agree to use an acceptable method(s) of contraception during heterosexual intercourse with a female partner capable of becoming pregnant while enrolled in the study
5. Males must agree to refrain from sperm donation during the study and for at least 90 days after study drug administration.
6. Body mass index from 18 to 32 kg/m2, inclusive.
7. Participants who are overtly healthy as determined by medical evaluation and judgment of the investigator including medical history, Physical Exam, laboratory tests, vital signs, and cardiac monitoring.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1.If male, have a female partner who is pregnant or planning to become pregnant during the study or within 90 days after study drug administration.
2.Have received any investigational drug, agent, or device within 30 days prior to Day 1, or current participation in another investigational study.
3. Have a positive result for Hepatitis B/C or HIV.
4. Have a positive test for drugs of abuse, cotinine, and/or alcohol
5. Current history of heavy tobacco/nicotine use.
6. Any serious or active medical or psychiatric illness, which could interfere with participant treatment, assessment, or compliance with the protocol.
7. Have a history of a gastrointestinal condition that could interfere with the absorption of the study drug
8. Have a history or symptoms of cardiovascular disease, including but not limited to coronary artery disease, hypertension, congestive heart disease.
9. Have a history of hematological disorders, including disorders such as a bleeding disorder or a risk of gastrointestinal bleeding.
10. Have a history of chronic liver disease or hepatic impairment,
11. Total bilirubin greater than the upper limit of the normal reference range at screening or on Period 1 Day -1.
12. Have symptoms of acute infection (such as those experienced with COVID, cold, flu, or febrile illness) within 2 weeks prior to Period 1 Day 1.
13. Have clinically significant abnormal hemoglobin as determined by the investigator at the screening evaluation
14. Have donated a unit of blood or had clinically significant blood loss within 30 days prior to Period 1 Day 1 or donated plasma within 7 days prior to Period 1 Day 1.
15. Have received any prescription medication, vaccines, or any nonprescription medication (including vitamins and herbal products) within 14 days prior to Period 1 Day 1,

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Pharmacokinetics
Statistical methods / analysis
PK parameters following single-dose administration will be determined using standard noncompartmental methods and actual sampling times utilizing a PK data analysis program (e.g., Phoenix WinNonlin or equivalent).
Safety will be assessed through AEs, measurement of vital signs, ECGs, neurological assessments, and clinical laboratory test results. All AEs reported and any concomitant medication intake will also be documented.
Part A
Plasma ONC201 and ONC207 (metabolite) concentrations will be listed and summarized by dose and timepoint. Individual and mean plasma and urine concentration-time profiles will be plotted. Plasma and urine ONC201 and ONC207 PK parameters will be listed and summarized by dose.
Dose proportionality in plasma ONC201 Cmax and AUCinf will be assessed; if AUCinf is not well estimated, AUClast will be used for dose proportionality assessment.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
9/08/2021
Actual
13/08/2021
Date of last participant enrolment
Anticipated
1/10/2021
Actual
15/09/2021
Date of last data collection
Anticipated
26/11/2021
Actual
21/10/2021
Sample size
Target
15
Accrual to date
Final
15
Recruitment outside Australia
Country [1] 23735 0
New Zealand
State/province [1] 23735 0

Funding & Sponsors
Funding source category [1] 308722 0
Commercial sector/Industry
Name [1] 308722 0
Chimerix, Inc.
Country [1] 308722 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Chimerix, Inc.
Address
2505 Meridian Parkway, Suite 100, Durham, NC USA 27713
Country
United States of America
Secondary sponsor category [1] 309620 0
None
Name [1] 309620 0
Address [1] 309620 0
Country [1] 309620 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 308645 0
Central Health & Disability Ethics Committee
Ethics committee address [1] 308645 0
Ethics committee country [1] 308645 0
New Zealand
Date submitted for ethics approval [1] 308645 0
14/06/2021
Approval date [1] 308645 0
06/07/2021
Ethics approval number [1] 308645 0
21/CEN/158

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 111414 0
Dr Chris Wynne
Address 111414 0
New Zealand Clinical Trials - Christchurch
264 Antigua Street
Christchurch 8140
Country 111414 0
New Zealand
Phone 111414 0
+64 3 3729477
Fax 111414 0
NA
Email 111414 0
chris.wynne@nzcr.co.nz
Contact person for public queries
Name 111415 0
Chris Wynne
Address 111415 0
New Zealand Clinical Trials - Christchurch
264 Antigua Street
Christchurch 8140
Country 111415 0
New Zealand
Phone 111415 0
+64 3 3729477
Fax 111415 0
NA
Email 111415 0
chris.wynne@nzcr.co.nz
Contact person for scientific queries
Name 111416 0
Chris Wynne
Address 111416 0
New Zealand Clinical Trials - Christchurch
264 Antigua Street
Christchurch 8140
Country 111416 0
New Zealand
Phone 111416 0
+64 3 3729477
Fax 111416 0
NA
Email 111416 0
chris.wynne@nzcr.co.nz

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.